FlexGen was a biotechnology company based in Leiden, Netherlands. FlexGen was a spin-off from Leiden University Medical Centre and Dutch Space (part of EADS) and had proprietary technologies for laser based in-situ synthesis of oligonucleotides and other biomolecules. On 21 December 2015, Flexgen Bv in Leiden (South Holland) was declared bankrupt by the court in Gelderland Source.
Products.
FleXelect.
FleXelect oligopools consist of custom oligonucleotides in solution and can be used for in solution target enrichment prior to next generation DNA sequencing. Target enrichment or In solution hybrid selection is a method for genomic selection in an increasing number of applications such as;
An example of a recent application is testing of the BRCA1 and BRCA2 breast cancer risk genes
FlexArrayer.
The FlexArrayer is an in-house custom oligonucleotide synthesis instrument. The FlexArrayer facilitates high throughput synthesis of FleXelect oligopools for in-solution target enrichment as well as custom microarray production. The FlexArrayer is also applicable for array based re-sequencing.
The FlexArrayer provides microarray and oligopool synthesis typically used by:
Technology.
Production of microarrays and FleXelect oligopools is done with the FlexArrayer (see image) using proprietary technology. The FlexArrayer synthesizes custom probesets on a substrate based on oligonucleotide deprotection technology;
References.
 ;templatestyles src="Reflist/styles.css" / ;